Clinical Trials
15 trialsNCT05398861 2026-04-16
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05769010 2026-04-01
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Phase 2 Recruiting
NCT07128251 2025-08-17
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Phase 2 Not yet recruiting
NCT07070713 2025-07-17
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT06788171 2025-01-23
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06293014 2024-03-05
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05675033 2023-01-09
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT05640726 2022-12-07
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Fujian Cancer Hospital
Phase 2 Unknown
NCT05357417 2022-09-16
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Phase 2 Unknown
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03126799 2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2 Unknown
NCT03240549 2017-08-07
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
Beijing Hospital
Phase 2 Unknown
NCT01296815 2015-07-27
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Phase 2 Completed
NCT01249521 2010-11-30
Vengeance
Austin Health
Phase 2 Unknown